에서 실시간으로 운영 중이에요!
자세히 알아보기
GridAI Technologies Corp
GRDX
GRDX
소개: GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
직원 수: 2
뉴스
긍정적
중립
부정적
투자 심리
3개월
긍정적
0%
중립
0%
부정적
0%
Lightweight Charts™를 사용해 가격 차트를 구현했어요.